Welcome to our dedicated page for REGENERON PHARMACEUTICALS SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
Pitofsky Jason reported multiple insider transaction types in a Form 4 filing for REGN. The filing lists transactions totaling 4,036 shares at a weighted average price of $684.14 per share. Following the reported transactions, holdings were 4,272 shares.
Regeneron Pharmaceuticals director Arthur F. Ryan reported selling 100 shares of the company’s common stock on February 9, 2026 in a series of small open-market trades. Reported sale prices ranged from about $775.63 to $787.82 per share.
The filing states these transactions were made under a Rule 10b5-1(c) trading plan adopted on October 31, 2025, which pre-schedules trades. Following the transactions, Ryan directly beneficially owned 17,803 shares of Regeneron common stock.
A person associated with the issuer has filed a Form 144 to potentially sell 400 shares of common stock through J.P. Morgan Securities LLC on or about 02/09/2026 on NASDAQ. The filing lists an aggregate market value of 314204 for these shares and notes that 103902660 shares of this class were outstanding. The 400 shares were originally acquired on 08/22/2013 from the issuer as compensation.
Regeneron Pharmaceuticals security holder plans to sell 2,036 common shares under Rule 144. The planned sale is through UBS Financial Services on NASDAQ, with an aggregate market value of 1,594,534.12 and 103,902,660 common shares stated as outstanding.
The shares to be sold were acquired from the issuer via two transactions: 1,000 shares through a cash exercise of stock options dated 02/09/2026, and 1,036 shares through a restricted stock award dated 12/08/2025.
Regeneron Pharmaceuticals, Inc. filed a Form 13F holdings report disclosing 2 holdings with an aggregate reported market value of $33,799,428. The report is signed by Leonard Brooks, Senior Vice President, Treasurer, and dated 02-06-2026. The filing lists the manager's address as 777 Old Saw Mill River Road, Tarrytown, NY.
Regeneron Pharmaceuticals reports full-year 2025 revenue of $14,342.9M, up slightly from 2024, and net income of $4,504.9M, with diluted EPS of $41.48. Growth is driven by key biologics and extensive collaborations.
Flagship eye drugs EYLEA HD and EYLEA together generated $7,891.0M in 2025 net product sales, while Dupixent global net product sales reached $17,806.7M. Libtayo, Praluent, Kevzara and other products added diversified revenue across immunology, oncology and cardiovascular disease.
The company highlights a broad late-stage pipeline in ophthalmology, immunology, oncology, hematology, neurology and rare diseases, with multiple Phase 3 programs and upcoming regulatory decisions through 2026–2027. Regeneron also underscores its VelociSuite antibody platforms and Regeneron Genetics Center as core innovation engines, supported by major partnerships with Sanofi, Bayer, Alnylam, Intellia and others.
Regeneron Pharmaceuticals, Inc. filed a current report to furnish a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 to the report.
The company states that the information provided under the results section, including Exhibit 99.1, is being furnished rather than filed under securities laws, which affects how it is treated for certain legal liabilities and incorporation by reference into other registration statements.
Regeneron Pharmaceuticals, Inc. used its appearance at the 44th Annual J.P. Morgan Healthcare Conference to share a corporate update that includes preliminary, unaudited financial information for the fourth quarter and full year 2025, furnished via an accompanying presentation.
For the fourth quarter 2025, Regeneron currently expects to record an acquired in-process research and development charge of approximately $19 million on a pre-tax basis, which is expected to reduce both GAAP and non-GAAP net income per diluted share by about $0.14. In addition, under its previously disclosed matching program supporting Good Days’ Retinal Vascular and Neovascular Disease Fund, Regeneron was notified of about $60 million in donations to the fund in the quarter, leading to a corresponding matching charge recorded in selling, general, and administrative expenses. All results remain preliminary and subject to completion of financial closing procedures.
Regeneron Pharmaceuticals director Bonnie L. Bassler reported an option exercise and share sale. On January 7, 2026, she exercised 1,500 Non-Qualified Stock Options with an exercise price of $374.12 per share, receiving 1,500 shares of common stock. That same day, she sold 1,500 common shares at a volume-weighted average price of $800.00 per share under a Rule 10b5-1(c) trading plan adopted on May 2, 2025. After these transactions, she directly held 1,703 shares of common stock and 2,861 stock options.